on Lir Life Sciences Corp. (CVE:SKNY)
Lir Life Sciences Announces New Study on Obesity Therapies
Lir Life Sciences Corp., based in Vancouver, has unveiled the design of a comparative animal study. This research focuses on cell-penetrating peptide-mediated delivery of GLP/GIP-based obesity therapies. The study aims to advance Lir's transdermal platform, promoting needle-free options for obesity treatments. GLP-1 and GIP improve metabolism and weight regulation, targeting obesity's core factors.
The study, in collaboration with scientific partners, aims to assess transdermal delivery effectiveness compared to traditional injections. Subjects will receive transdermal formulations followed by an oral glucose challenge. Success will be measured by monitoring blood glucose levels.
The results will guide Lir's future research, identifying the most promising drug candidates for further development. CEO Edward Mills emphasizes the goal to find the best candidates for transdermal delivery, influencing their IND strategy.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Lir Life Sciences Corp. news